Patents by Inventor Thomas Meinicke

Thomas Meinicke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Medical Use of Pharmaceutical Combination or Composition
    Publication number: 20230381188
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.
    Type: Application
    Filed: August 7, 2023
    Publication date: November 30, 2023
    Inventors: Thomas MEINICKE, Maximilian VON EYNATTEN
  • MEDICAL USE OF PHARMACEUTICAL COMBINATION OR COMPOSITION
    Publication number: 20210205315
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.
    Type: Application
    Filed: March 23, 2021
    Publication date: July 8, 2021
    Inventors: Thomas MEINICKE, Maximilian VON EYNATTEN
  • Medical use of pharmaceutical combination or composition
    Publication number: 20200171038
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 4, 2020
    Inventors: Thomas MEINICKE, Maximilian VON EYNATTEN
  • MEDICAL USE OF PHARMACEUTICAL COMBINATION OR COMPOSITION
    Publication number: 20190060320
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.
    Type: Application
    Filed: October 25, 2018
    Publication date: February 28, 2019
    Inventors: Thomas MEINICKE, Maximilian VON EYNATTEN
  • Medical use of pharmaceutical combination or composition
    Patent number: 10155000
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: December 18, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Meinicke, Maximilian Von Eynatten
  • Medical Use of Pharmaceutical Combination or Composition
    Publication number: 20170354660
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.
    Type: Application
    Filed: June 8, 2017
    Publication date: December 14, 2017
    Inventors: Thomas MEINICKE, Maximilian VON EYNATTEN
  • PHARMACEUTICAL COMPOSITIONS COMPRISING BI-1356 AND METFORMIN
    Publication number: 20160038501
    Abstract: The present invention relates to therapeutic uses of pharmaceutical compositions or combinations of a DPP-4 inhibitor with metformin.
    Type: Application
    Filed: October 23, 2015
    Publication date: February 11, 2016
    Inventor: Thomas MEINICKE
  • PHARMACEUTICAL COMPOSITIONS COMPRISING BI-1356 AND METFORMIN
    Publication number: 20120219623
    Abstract: The present invention relates to therapeutic uses of pharmaceutical compositions or combinations of a DPP-4 inhibitor with metformin.
    Type: Application
    Filed: October 1, 2010
    Publication date: August 30, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventor: Thomas Meinicke
  • Pharmaceutical Combination of Angiotensin II Antagonists and Angiotensin I Converting Enzyme Inhibitors
    Publication number: 20080146639
    Abstract: A method of treatment of indications which can be positively influenced by inhibition of AT1 mediated effects with maintenance of AT2 receptor mediated effects of angiotensin II and by ACE inhibition, thus also increasing bradykinin mediated effects, e.g., to reduce the incidence of stroke, acute myocardial infarction or cardiovascular death, or of indications associated with the increase of AT1 receptors in the subepithelial area or increase of AT2 receptors in the epithelia, comprising coadministration of effective amounts of an angiotensin II antagonist and an ACE inhibitor, pharmaceutical compositions containing an angiotensin II antagonist together with an ACE inhibitor and the use of an angiotensin II antagonist and an ACE inhibitor for the manufacture of corresponding pharmaceutical compositions.
    Type: Application
    Filed: February 21, 2008
    Publication date: June 19, 2008
    Applicant: Boehringer Ingelheim Pharma GmbH & Co Kg.
    Inventors: Peter BOEHM, Wolf Thomas MEINICKE, Axel RIEDEL
  • Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
    Publication number: 20030171415
    Abstract: A method of treatment of indications which can be positively influenced by inhibition of AT1 mediated effects with maintenance of AT2 receptor mediated effects of angiotensin II and by ACE inhibition, thus also increasing bradykinin mediated effects, e.g., to reduce the incidence of stroke, acute myocardial infarction or cardiovascular death, or of indications associated with the increase of AT1 receptors in the subepithelial area or increase of AT2 receptors in the epithelia, comprising coadministration of effective amounts of an angiotensin II antagonist and an ACE inhibitor, pharmaceutical compositions containing an angiotensin II antagonist together with an ACE inhibitor and the use of an angiotensin II antagonist and an ACE inhibitor for the manufacture of corresponding pharmaceutical compositions.
    Type: Application
    Filed: January 30, 2003
    Publication date: September 11, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Peter Boehm, Wolf Thomas Meinicke, Axel Riedel